KL-A167 not checked

Kelun-Biotech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.”In the company’s words, NCT05294172 on ClinicalTrials.gov
Tested for
Nasopharyngeal Carcinoma, Recurrent or Metastatic, Non-small Cell Lung Cancer, Small Cell Lung Cancer
Main trialPhase 3
“The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1”In the company’s words, NCT05294172 on ClinicalTrials.gov

Other drugs for Nasopharyngeal Carcinoma

All 15 drugs for Nasopharyngeal Carcinoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2027 KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2Recruiting Aug 2026 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 2Recruiting 31 Dec 2028 SKB500 Combinations in Patients With Small Cell Lung Cancer
Phase 2Completed 22 Aug 2020 An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
Phase 2Completed 13 Jul 2021 KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2Completed 31 Jul 2026 SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KL-A167

Following is part of Solo: you see every change to KL-A167 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in